SCIENTIFIC PROGRAM (FINAL VERSION)

“EMERGING TARGETED THERAPIES IN CANCER & AUTOIMMUNITY” SYMPOSIUM

April 21 (Room 1)

OPENING SESSION:

17.30 - 17.35 Welcome speech (Isis Torrens, Head of Pharmaceutical Department, CIGB)
17.35-17.40 Presentation of the Scientific Program (Silvio Perea, President of the Scientific Committee)

17.40-18.00 Opening lecture 1: Progress on the Biomedical Research pipeline at the Center for Genetic Engineering & Biotechnology, Havana, Cuba (Marta Ayala, Deputy Director of CIGB)

18.00- 18.30 Opening lecture 2: Epigenetic reprogramming of cancer cells: targeting metastatic and dormant cancer cell phenotypes to effect lasting cures (Frank Rauscher, Wistar Institute Cancer Center, Philadelphia, USA)
April 22 (Room 1)

TOPIC: CANCER BIOLOGY AND NOVEL TARGETS (08.45-13.15)

Chairs: Pamela Stanley (USA)/Silvio E Perea (CUBA)

08.45-09.15 MOLECULAR TARGETING FOLLOWED BY DRUG RESISTANCE: THE STORY THE EUKARYOTIC TRANSLATION INITIATION FACTOR EIF4E IN LEUKEMIA (Katherine LB Borden, Canada)

09.20-09.40 PROTEIN KINASE CK2 AS AN EMERGING ONCOLOGY TARGET: LESSONS FROM THE CIGB-300 PEPTIDE INHIBITOR (Silvio E Perea, Cuba)

09.45-10.05 ROLES FOR GLYCANS IN CANCER AND NOTCH SIGNALING (Pamela Stanley, USA)

10.10-10.30 INTERPLAY BETWEEN NRF2 AND AUTOPHAGY ENHANCES TUMOR VIROTHERAPY BY CURTAILING INNATE ANTIVIRAL IMMUNITY (David Olagnier, Canada)

10.35-10.50 Coffee break

Chairs: Katherine LB Borden (Canada)/Yasser Perera (CUBA)

10.50-11.10 ABROGATION OF CASEIN KINASE 2 (CK2)-MEDIATED SIGNALING USING A PEPTIDE INHIBITOR IMPAIRS VIABILITY AND PROLIFERATION OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS (Yasser Perera, Cuba)

11.15-11.35 ABCB5 CONTROLS COLORECTAL CANCER APOPTOSIS RESISTANCE (Natasha Frank, USA)

11.40-12.00 POTENTIATION OF THE ANTI-CANCER EFFECTS OF SMAC MIMETICS IN COMBINATION WITH IMMUNOSTIMULANTS (Shawn Beug, Canada)

12.05-12.25 ACTIVE-SITE mTOR INHIBITORS AUGMENT HSV1 INFECTION OF CANCER CELLS WITH ELEVATED eIF4E ACTIVITY (Tommy Alain, Canada)

12.30-12.50 THE MANNOSE RECEPTOR LY75 (DEC205/CD205) MODULATES CELLULAR PHENOTYPE AND METASTATIC POTENTIAL OF OVARIAN CANCER CELLS (Dimcho Bachvarov, Canada)

12.55-13.15 CIGB-552 AND ASPIRIN SYNERGISTICALLY INHIBIT THE NFKB ACTIVATION IN SW480 COLON CANCER CELL (Brizaida Oliva, CUBA)

15.00-17.00 POSTER PRESENTATION
“EMERGING TARGETED THERAPIES IN CANCER” SYMPOSIUM

April 23 (Room 1)

TOPIC: ANGIogenesis (08.45-10.35)

Chairs: Robert Kerbel (Canada)/Mónica Bequet (CUBA)

**08.45-09.15** Experimental Therapeutics Investigated in Preclinical Models of Early or Late Stage Metastatic Disease *(Robert Kerbel, Canada)*

**09.20-09.40** Drug Resistance in the Era of Stromal-Targeted Therapy: Lessons from Antiangiogenic Inhibitors *(John M.L Ebos, USA)*

**09.45-10.05** Peptide-Based Vehicles for Tumor Vascular Targeting with Cytokines *(Angelo Corti, Italy)*

**10.10-10.30** Oncogenic Modifiers of Exosomal Communication Within the Vascular Tumour Microenvironment - Therapeutic and Biomarker Implications *(Janusz Rak, Canada)*

**10.35-10.50** Coffee break

TOPIC: IMMUNOTHERAPY (10.50-13.15)

Chairs: Markus Frank (USA)/Isis Torrens (CUBA)

**10.50-11.10** Specific Active Immunotherapy with a VEGF Targeted Vaccine for Cancer, From Preclinical to Clinical Trials - Where We Stand? *(Marta Ayala, CUBA)*

**11.15-11.35** Combination of IAP Antagonism and Immune Checkpoint Blockade to Treat Cancer *(Robert Korneluk, Canada)*

**11.40-12.00** Unitarg, a Novel Modular Platform Technology Allowing to Combine BITE and CAR Technology for Retargeting of Tumor Cells *(Michael Bachmann, Germany)*

**12.05-12.25** Stem Cell-Mediated Immunomodulation in Normal Skin and Skin-Associated Malignancy *(Markus Frank, USA)*

**12.30-13.10** How CRADAS and Grants Enable 'Bench to Bedside' New Molecular Medicines for Diagnosis and Treatment of Rare and Pediatric Diseases *(Stanley Satz, USA)*
“EMERGING TARGETED THERAPIES IN CANCER” SYMPOSIUM

April 24 (Room 1)

TOPIC: TRANSLATIONAL & CLINICAL CANCER RESEARCH (08.45-11.20)

Chairs: James W Larrick (USA) /Iraldo Bello (CUBA)

08.45-09.15 ANTIBODY-DIRECTED ACTIVATED T CELL CANCER IMMUNOTHERAPY (James W Larrick, USA)

09.20-09.40 TRANSLATING IMMUNOLOGICAL EVALUATIONS FOR A VEGF-BASED VACCINE: FROM BENCH TO BEDSIDE (Mónica Bequet, CUBA)

09.45-10.05 ALPHA-FETOPROTEIN+TOXIN COMPLEX AS CANCER IMMUNOTHERAPY (Vladimir Pak, Canada)

10.10-10.30 GENOMIC MODIFICATION OF IMMUNE SYSTEM CELLS FOR THE TREATMENT OF AIDS (Daniel Bachiller, Spain)

10.35-10.55 THE CLINICAL PERSPECTIVE OF TRANSLATIONAL MULTIMODAL THERAPEUTIC APPROACHES TO ADVANCED UROLOGICAL TUMORS (Carine Pecqueux, Germany)

11.00-11.20 THE ROLE OF HEBERFERON IN THE TREATMENT OF SOLID AND BRAIN TUMORS (Iraldo Bello, CUBA)

“EMERGING TARGETED THERAPIES IN CANCER” SYMPOSIUM

April 24 (Room 2)

TOPIC: NEUROONCOLOGY (08.45-10.40)

Chairs: Melchor Alvarez (Spain)/Maria del Carmen Abrahantes (Cuba)

08.45-09.15 THERAPY AND DIAGNOSTIC OF GLIOMA (Melchor Alvarez, Spain)

09.20-09.45 IT IS IMPORTANT TO ACHIEVE GROSS TOTAL RESECTION OF BRAIN GLIOMAS? CONTRIBUTION OF INTRAOPERATIVE MRI (REMAIN), TO DO THIS (Roberto Herrera, Argentine)

09.50-10.10 IMAGE GUIDANCE IN GLIOMA SURGERY (Jose L Ledesma, Argentine)

10.15-10.35 MICRO-NANOFORMULATIONS FOR CANCER THERAPY AND DIAGNOSIS (Eusebio Gainza, Spain)